InsiderTrades

Form 4/A for FTH Faeth Therapeutics, Inc.

Accepted 2023-03-29 00:00:00 ET · period of report 2023-02-15 · accession 0001209191-23-021540 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMA 2023-03-29 2023-02-15 FTH Gallagher Patrick Stephen Chief Business Off A - Grant $0.00 +43.5K 29.3K New $0
DA 2023-03-29 2023-02-15 FTH Gallagher Patrick Stephen Chief Business Off A - Grant $0.00 +60.0K 60.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-15 A A 14,200 $0.00 43,513 D — — (F3) These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date. (F1) This amendment is being filed solely to correct the number of shares beneficially owned, which the original filing overreported by two shares.
2 Common Common Stock 2023-02-15 A A 29,313 $0.00 29,313 D — — (F1) This amendment is being filed solely to correct the number of shares beneficially owned, which the original filing overreported by two shares. (F2) These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.
3 Derivative Stock Option (Right to Buy) 2023-02-15 A A 60,000 $0.00 60,000 D $1.43 · — to 2023-02-14 60,000 Common Stock (F4) The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.